NR1D1抑制剂在制备用于治疗脓毒症的药物中的用途
By preparing NR1D1 inhibitor-loaded nanovesicles, the NR1D1 gene is silenced, restoring the circadian rhythm and immune function of macrophages. This solves the problem of irreversible immunosuppression in existing sepsis treatments, achieving efficient immune function recovery and reducing the risk of secondary infections.
Patent Information
- Application Number
- CN202610250354.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-03
- Publication Date
- 2026-07-17
- Estimated Expiration
- 2046-03-03
AI Technical Summary
Current treatments for sepsis cannot effectively reverse the state of immunosuppression; antibiotics only target pathogens and cannot improve immune function; immunostimulants may cause excessive inflammation; and organ support therapy is symptomatic rather than an intervention for the underlying cause.
Drug-loaded nanovesicles were prepared using NR1D1 inhibitors. By targeting and silencing the NR1D1 gene with siRNA, and utilizing the vesicle membrane fused with erythrocyte membrane, macrophage membrane, cardiolipin, cholesterol and lecithin, the precise targeting and responsive release of siRNA was achieved, restoring the circadian rhythm and immune function of macrophages.
It significantly improves the immune function of sepsis patients, reduces the risk of secondary infections, increases survival rate, restores circadian rhythm disordered activity and sleep patterns, reduces bacterial load, and avoids systemic off-target effects and toxic side effects.
Smart Images
Figure CN121775000B_ABST
Abstract
Citation Information
Patent Citations
Drug-loaded nano vesicle as well as preparation method and application thereof
CN121754506A